Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa
2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV)
ribonucleic acid (RNA) levels